TG THERAPEUTICS, INC. Cash and Restricted Cash
TG THERAPEUTICS, INC. (TGTX) had Cash and Restricted Cash of $483.94 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $483.94M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $443.56M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $80.49M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $75.41M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $483.94M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $443.56M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $80.49M 10-K · filed 2026-02-27 |
| 2025-09-30 | $75.41M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $130.44M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $133.44M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $181.19M 10-K · filed 2026-02-27 |
| 2024-09-30 | $197.12M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $84.20M 10-Q · filed 2025-08-08 |
| 2024-03-31 | $76.77M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $94.22M 10-K · filed 2026-02-27 |
| 2023-09-30 | $152.18M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $98.29M 10-Q · filed 2024-08-09 |
| 2023-03-31 | $62.74M 10-Q · filed 2024-05-06 |
| 2022-12-31 | $103.58M 10-K · filed 2025-03-03 |
| 2022-09-30 | $111.13M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $148.34M 10-Q · filed 2023-08-04 |
| 2022-03-31 | $186.94M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $300.15M 10-K · filed 2024-02-29 |
| 2021-09-30 | $327.77M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $402.97M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $472.77M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $554.70M 10-K · filed 2023-03-01 |
| 2020-09-30 | $255.41M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $261.77M 10-Q · filed 2021-08-06 |
| 2020-03-31 | $53.30M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $113.89M 10-K · filed 2023-03-01 |
| 2019-09-30 | $45.92M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $58.47M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $65.59M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $43.20M 10-K · filed 2022-03-01 |
| 2018-09-30 | $71.96M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $106.91M 10-Q · filed 2019-08-09 |
| 2018-03-31 | $83.48M 10-Q · filed 2019-05-10 |
| 2017-12-31 | $57.30M 10-K · filed 2021-03-01 |
| 2017-09-30 | $92.43M 10-Q · filed 2018-11-09 |
| 2017-06-30 | $78.19M 10-Q · filed 2018-08-09 |
| 2017-03-31 | $96.22M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $25.61M 10-K · filed 2020-03-02 |
| 2015-12-31 | $55.64M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |